On Monday, Regenxbio Inc (NASDAQ: RGNX) was -3.90% drop from the session before settling in for the closing price of $8.21. A 52-week range for RGNX has been $6.56 – $28.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 111.76% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 21.49%. With a float of $44.60 million, this company’s outstanding shares have now reached $49.53 million.
In an organization with 344 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Regenxbio Inc stocks. The insider ownership of Regenxbio Inc is 9.97%, while institutional ownership is 79.08%. The most recent insider transaction that took place on Dec 30 ’24, was worth 148,504. Before that another transaction happened on Oct 01 ’24, when Company’s Director sold 10,000 for $10.11, making the entire transaction worth $101,052. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.49% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
You can see what Regenxbio Inc (RGNX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.61 million. That was inferior than the volume of 1.04 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.54%. Additionally, its Average True Range was 0.58.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 19.22%, which indicates a significant decrease from 43.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.44% in the past 14 days, which was lower than the 73.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.21, while its 200-day Moving Average is $11.27. However, in the short run, Regenxbio Inc’s stock first resistance to watch stands at $8.26. Second resistance stands at $8.63. The third major resistance level sits at $8.88. If the price goes on to break the first support level at $7.64, it is likely to go to the next support level at $7.39. The third support level lies at $7.02 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
There are 49,545K outstanding shares of the company, which has a market capitalization of 390.91 million. As of now, sales total 90,240 K while income totals -263,490 K. Its latest quarter income was 24,200 K while its last quarter net income were -59,600 K.
